18 June 2021
This week with the announcement of 20,000 women in the UK receiving a letter about the risks of Sodium Valproate in Pregnancy we have worked and liased with the General Medical Council and The General Pharmaceutical Society in producing further communications and a Video to highlight the risk.
Here at INFACT we welcome and thank all involved in this round of communications and continued effort for safer prescribing with Sodium Valproate.
General Medical Council : This case study is about discussing the risk of taking sodium valproate with a mother who’s been prescribed it for several years.
We’ve developed this case study with the General Pharmaceutical Council and the Nursing and Midwifery Council. While the characters are fictional, the case study is based on several people’s lived experiences, which were generously shared by patients and clinicians.
It highlights the risk of harm created by taking sodium valproate (‘valproate’), a medication for epilepsy that can cause birth defects if taken during pregnancy. Valproate was one of the interventions considered by the Independent Medicines and Medical Devices Safety Review, which reported in July 2020. The Review highlighted that many women had not been properly informed about the risks of taking valproate.
The MHRA’s strengthened regulatory position should mean that no more women are prescribed sodium valproate without discussing the risks of harm and having a Pregnancy Prevention Plan in place. However, for some women already taking valproate but unaware of the risks this can create complex situations and difficult conversations with their healthcare providers. Repeat prescription (GP)
Be familiar with guidelines and developments that affect your work.
Make sure any repeat prescription you sign is safe and appropriate.
Don’t assume a patient’s already been given the information they need about risks of harm. If you haven’t personally spoken to a patient about medication they’re taking, it may be particularly important to review their decision to take it.
Dr Wright receives a repeat prescription request for sodium valproate from Millie, who is new to the practice. She sees that a valproate annual risk acknowledgement form has not been completed.
After reviewing Millie’s medical record, Dr Wright becomes concerned because it appears that:
- Millie has been prescribed valproate continuously since 2010
- she hasn’t seen a neurologist since 2012
- she doesn’t appear to be on the pregnancy prevention programme (PPP).
Dr Wright wonders whether Millie has been advised about the risks of taking valproate during pregnancy. She notes that Millie’s two children were both born before 2018 when the Medicines and Healthcare products Regulatory Agency (MHRA)’s strengthened regulatory position came into force. This made it compulsory for GPs to make sure, each time a repeat prescription is issued, that women of childbearing potential on valproate are:
- supported by a PPP
- have an up to date, signed, Annual Acknowledgement of Risk Form (AARF)
- are having an annual review with a specialist.
Dr Wright wonders whether Millie’s valproate use throughout pregnancy may have adversely affected her children.
She asks the practice receptionist to phone Millie and ask her to attend the surgery for a medication review with Dr Wright as soon as possible.Medication review (GP)
General Pharmaceutical Council
This week the General Pharmaceutical Council have also reiterated communications to Pharmacists in England Scotland and Wales. In collaboration with GPC we have created a video explaining the role the Pharmacist has when prescribing Sodium Valproate
|Valproate updates , |
We wanted to share with you a letter that NHS England & Improvement are sending to all women and girls taking valproate in England. The letter includes a reminder about the risks of taking valproate during pregnancy and the need for an annual review.
This letter also encourages patients to speak to their doctor or nurse specialist. Your patients taking valproate may also ask to speak to you about the letter and you may want to check with your patients if they have received the letter and if they have any questions about their valproate prescription.
|Medicines in Pregnancy Registry NHS Digital and the Medicines and Healthcare products Regulatory Agency (MHRA) have developed a valproate registry. |
Data collected in England between April 2018 and September 2020 shows:
47,532 females (ages 0-54) were prescribed one or more prescriptions for valproate in one or more months within the reporting period
180 females were prescribed valproate while pregnant
238 females stopped receiving prescriptions of valproate prior to their pregnancy
Supplying valproate safely to women and girls Pharmacy professionals have a key role in supplying valproate safely. Valproate must not be used in any woman or girl able to have children unless there is a pregnancy prevention programme (PPP) in place.
For women and girls, when they are dispensed valproate, they should expect:to be provided with a Patient Card every time valproate is dispensedfor valproate to be dispensed with a copy of the patient information leaflet, and if repackaged, with a warning on the container supplied to be reminded of the risks in pregnancy and the need for highly effective contraception, and a reminder of the need for annual specialist review to be asked if they have received the Patient GuideYou must make sure that the patient label is not placed over the warning labels or warning sticker on the box. Women taking valproate have shared with us examples of where this has happened.
When patients are visiting pharmacies for pregnancy tests or emergency hormonal contraception remember to ask them about any medications they are taking so you can provide further advice if their medicines are teratogenic.
Find out more about what you need to do in our Focus on supplying medicines safely: sodium valproate.
Watch our film where we speak to two women whose children were affected by exposure to sodium valproate during their pregnancies, to find out why it’s so important to make sure that women are made aware of the risks when dispensing sodium valproate. Valproate case study This in-depth case study explores patient Millie’s interactions with the different healthcare professionals she meets. It explores how to approach difficult conversations and highlights the important role all healthcare professionals have in prescribing and dispensing valproate safely. How pharmacies can support women and girls taking valproate Find out more in this example of notable practice on supporting people taking valproate from our Knowledge Hub.
Our inspectors check the pharmacy team are following the requirements of the Pregnancy Prevention Programme during inspections.